Selecta Biosciences Inc. (NASDAQ: SELB) is 4.29% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $4.83 in the current 52-week trading range. The SELB stock was last observed hovering at around $2.92 in the last trading session, with the day’s gains setting it 0.24% off its average median price target of $4.75 for the next 12 months. It is also 75.69% off the consensus price target high of $13.00 offered by 7 analysts, but current levels are -58.0% lower than the price target low of $2.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $3.16, the stock is 0.80% and -0.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.01 million and changing 8.22% at the moment leaves the stock 12.90% off its SMA200. SELB registered 12.06% gain for a year compared to 6-month gain of 16.18%. The firm has a 50-day simple moving average (SMA 50) of $3.1874 and a 200-day simple moving average (SMA200) of $2.7374.
The stock witnessed a -1.56% loss in the last 1 month and extending the period to 3 months gives it a 92.68%, and is 3.27% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.46% over the week and 7.01% over the month.
Selecta Biosciences Inc. (SELB) has around 27 employees, a market worth around $341.34M and $11.30M in sales. Distance from 52-week low is 122.54% and -34.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-192.10%).
Selecta Biosciences Inc. (SELB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Selecta Biosciences Inc. (SELB) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 2.30, where 3 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Selecta Biosciences Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.12 with sales reaching $6.37M over the same period.The EPS is expected to grow by 58.40% this year, but quarterly earnings will post 68.20% year-over-year. Quarterly sales are estimated to shrink -4.30% in year-over-year returns.
Selecta Biosciences Inc. (SELB) Top Institutional Holders
108 institutions hold shares in Selecta Biosciences Inc. (SELB), with 28.13M shares held by insiders accounting for 26.03% while institutional investors hold 87.08% of the company’s shares. The shares outstanding are 105.33M, and float is at 79.91M with Short Float at 10.36%. Institutions hold 64.41% of the Float.
The top institutional shareholder in the company is BVF Inc. with over 8.46 million shares valued at $20.98 million. The investor’s holdings represent 7.83% of the SELB Shares outstanding. As of Sep 29, 2020, the second largest holder is Mangrove Partners with 5.79 million shares valued at $14.35 million to account for 5.36% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 4.67 million shares representing 4.33% and valued at over $11.59 million, while Artal Group S.A. holds 4.17% of the shares totaling 4.5 million with a market value of $11.16 million.
Selecta Biosciences Inc. (SELB) Insider Activity
A total of 15 insider transactions have happened at Selecta Biosciences Inc. (SELB) in the last six months, with sales accounting for 2 and purchases happening 13 times. The most recent transaction is an insider purchase by TRABER PETER G, the company’s Chief Medical Officer. SEC filings show that TRABER PETER G bought 40,000 shares of the company’s common stock on Dec 14 at a price of $3.24 per share for a total of $0.13 million. Following the purchase, the insider now owns 40000.0 shares.
Selecta Biosciences Inc. disclosed in a document filed with the SEC on Dec 02 that Brunn Carsten (President and CEO) sold a total of 3,323 shares of the company’s common stock. The trade occurred on Dec 02 and was made at $3.35 per share for $11134.0. Following the transaction, the insider now directly holds 0.1 million shares of the SELB stock.
Still, SEC filings show that on Oct 23, SPRINGER TIMOTHY A (Director) acquired 994,488 shares at an average price of $2.71 for $2.7 million. The insider now directly holds 14,480,948 shares of Selecta Biosciences Inc. (SELB).
Selecta Biosciences Inc. (SELB): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -19.23% down over the past 12 months. Short interest in the company’s stock has fallen -16.91% from the last report on Nov 12, 2020 to stand at a total of 9.68 million short shares sold with a short interest ratio of 5.41.